VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
05/05/25, 5:41 AM
Location
zurichIndustry
biotechnology
health care
Type
partnership
VERAXA Biotech AG has announced a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate program targeting solid tumors. This partnership combines VERAXA's proprietary ADC technology with OmniAb's antibody discovery technology for the development of therapies targeting solid tumors.
Company Info
Location
zurich, zurich, switzerland
Additional Info
VERAXA Biotech AG develops next-generation cancer therapies using proprietary technology. Its BiTAC platform aims to enhance safety and efficacy of treatments. The company is advancing multiple drug candidates in the oncology sector.